Clinical Trial Update: Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial of a vaccine therapy combined with interleukin-12 for metastatic prostate cancer that is hormone-refractory has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Interleukin-12 (interleukin-12)
• Vaccine therapy

Snippet

Sponsor: University of Chicago | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED